retatrutide regulatory approval vs Semaglutide and Tirzepatide: GLP-3 Facts explained ⚠️ BEWARE OF RETATRUTIDE SOLD

Verify the output periodically using pH strips

Carry powder vials in your carry-on bag instead

Phase 2 data demonstrated LDL cholesterol reductions of approximately 20%, a finding researchers have attributed to glucagon agonism-mediated effects on PCSK9 degradation

This reduction may compromise the liver's ability to manage oxidative stress and perform detoxification, potentially contributing to disease progression

Next-generation agents include CagriSema (semaglutide + cagrilintide, NDA filed December 2025, showing 22.7% weight loss), retatrutide (triple GIP/GLP-1/glucagon agonist, 28.7% weight loss in Phase 3), and orforglipron (oral non-peptide GLP-1, submitted to FDA)

Proteomic analysis revealed that the oomyceticide phosphite exhibits multi-modal action in an oomycete pathosystem